New Delhi & Pune, 28th December 2020: Serum Institute of India, the largest vaccine manufacturer in the world by doses, announces the launch of India’s first indigenously developed pneumococcal vaccine – PNEUMOSIL®; in the presence of Dr. Harsh Vardhan, Minister of Health and Family Welfare today. PNEUMOSIL® as been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries.
Driven by the philanthropic commitment of SII to protect every family with affordable vaccines, PNEUMOSIL® comes with the advantage of presence of stereotypes 6A & 19A. The composition of the WHO pre-qualified vaccineis specially tailored as per the prevalence of the Top 10 serotypes of S. pneumoniae in India and other regions of the world, which is the unique feature of this conjugate vaccine. The vaccine will provide effective and long-lasting protection for children against pneumococcal diseases.
With this, SII further cements its position as the leader in the conjugate vaccines. It has several patents related to the manufacturing of this vaccine to its credit. This makes PNEUMOSIL® relatively cost-efficient at high-volumes and more accessible over the long term for the countries that need it most.
Speaking about the launch, Dr. Harsh Vardhan, Union Minister, Ministry of Health & Family Welfare said, “It is a great moment of pride to witness Serum Institute take forward the ‘Make in India’ legacy, with the launch of India’s first indigenously developed Pneumococcal Conjugate Vaccine. It is a significant milestone for the country’s public health care which will ensure that children are protected better against Pneumococcal disease with an affordable and high-quality vaccine. I am sure, Serum Institute of India will continue their endeavour to develop many more life saving vaccines in future also on the lines of clarion call of our Hon’ble Prime Minister “VOCAL FOR LOCAL” and fulfill our Hon’ble Prime Minister’s dream 'ATMANIRBHARBHARAT'”.
Talking about the launch of Pneumosil, Mr. Adar Poonawalla, CEO of Serum Institute of India shared, “Over the years our constant endeavor has been to provide high quality vaccines with regular supplies which ensures excellent immunization coverage to children and families worldwide. With that thought we have developed this PCV with a unique composition based on the serotype prevalence in India. This makes our PCV an ideal choice for protecting our children from pneumococcal disease. While the vaccine itself is of the highest quality and grade available, vaccine accessibility is of utmost importance as well, and to ensure ease of access by making it available at an affordable price. With the best PCV, we hope to bring down the mortality rate significantly while also making our country self-sufficient with a robust public health care system."
Pneumococcal disease is a significant contributor to the under-five mortality rate worldwide. Annually, India witnesses an estimated 71% of pneumonia deaths and 57% of severe pneumonia cases. Every year nearly 67,800 children under 5 years of age die India from pneumococcal diseases in 2018, recognizing it’s widespread fatality, WHO recommends the inclusion of Pneumococcal Conjugate Vaccine (PCV) in routine childhood immunization programs in all countries. Following this, Polysaccharide Conjugate Vaccines (PCV) work directly to reduce the incidence of pneumococcal pneumonia by preventing Streptococcus pneumonia.
The vaccine makes the Serum Institute of India the world’s third supplier of pneumococcal conjugate vaccines (PCV) under the pneumococcal Advance Market Commitment (AMC), and the first developing country vaccine manufacturer to access the global PCV market.
About Serum Institute of India Pvt. Ltd. (SIIPL)
Driven by the philanthropic philosophy of affordable vaccines;Serum Institute of India Pvt, Ltd.(SIIPL) is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world's cheapest and WHO accredited vaccines to as many as 170 countries. It was founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs including vaccines worldwide. With a strong commitment towards global health, the institute’s objective has been proliferated by bringing down the prices of newer vaccines such as such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. SII is credited with bringing world-class technology to India, through its state-of-the-art equipped multifunctional production facility in Manjri, Pune; association with Zipline and government agencies to transform emergency medicine and critical care along with spearheading the race of vaccine development against the COVID-19 pandemic.
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.